Document Detail

An effective regimen for early medical abortion: a report of 2000 consecutive cases.
MedLine Citation:
PMID:  9804263     Owner:  NLM     Status:  MEDLINE    
A combination of the anti-progesterone mifepristone and gemeprost provides an effective non-surgical method for the induction of abortion at gestations up to 63 days, achieving complete abortion rates of over 95%. We report our experience with an alternate regimen, comprising a reduced dose of mifepristone in combination with vaginal misoprostol. A consecutive series of 2000 women requesting early medical abortion at gestations up to 63 days was studied retrospectively. Each woman received mifepristone 200 mg orally, followed 36-48 h later by misoprostol 800 microg vaginally. Of the 2000 women, 39 (2.0%) aborted completely following administration of mifepristone alone and a further 1912 experienced complete abortion following administration of misoprostol (a complete abortion rate of 97.5%). Surgical intervention was required in 49 women (2.5%): for incomplete abortion in 27 (1.4%), for missed abortion in seven (0.4%), for continuing pregnancy in 11 (0.6%) and to exclude ectopic pregnancy in four (0.2%). The surgical intervention rate was significantly higher among women at gestations > or = 49 days than among those at < or = 49 days (3.3 versus 1.5%, P = 0.0193). The regimen appears as effective, in terms of high complete abortion rate and low continuing pregnancy rate, as any published alternative. This regimen has the benefit of being less costly as the dose of mifepristone is 67% lower and misoprostol is substantially less expensive than gemeprost. Additionally, misoprostol does not require special transport or storage requirements. As such, the combination of mifepristone and misoprostol may be preferable to mifepristone and gemeprost.
P W Ashok; G C Penney; G M Flett; A Templeton
Related Documents :
339283 - 15(s)15-methyl prostaglandin f2alpha for termination of very early human pregnancy. a c...
3945463 - Adverse effects of pregnancy on multifocal eosinophilic granuloma.
20971713 - Obesity in pregnancy: a major healthcare issue.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  13     ISSN:  0268-1161     ISO Abbreviation:  Hum. Reprod.     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1999-01-19     Completed Date:  1999-01-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  2962-5     Citation Subset:  IM    
Department of Obstetrics & Gynaecology, University of Aberdeen, Aberdeen Maternity Hospital, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortifacient Agents, Nonsteroidal / administration & dosage
Abortifacient Agents, Steroidal / administration & dosage
Abortion, Incomplete / etiology,  surgery
Abortion, Induced / adverse effects,  methods*
Gestational Age
Middle Aged
Mifepristone / administration & dosage
Misoprostol / administration & dosage
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Abortifacient Agents, Steroidal; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Obstetric outcome after prenatal diagnosis in pregnancies obtained after intracytoplasmic sperm inje...
Next Document:  The cobweb syndrome: first trimester sonographic diagnosis of multiple amniotic bands confirmed by f...